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Abstract 
Background: Type 2 diabetes is a major healthcare problem. Glucose-, lipid-, and blood pressure-lowering strategies 
decrease the risk of micro- and macrovascular complications. However, a substantial residual risk remains. To unravel 
the etiology of type 2 diabetes and its complications, large-scale, well-phenotyped studies with prospective follow-up 
are needed. This is the goal of the DiaGene study. In this manuscript, we describe the design and baseline characteris-
tics of the study.
Methods: The DiaGene study is a multi-centre, prospective, extensively phenotyped type 2 diabetes cohort study 
with concurrent inclusion of diabetes-free individuals at baseline as controls in the city of Eindhoven, The Nether-
lands. We collected anthropometry, laboratory measurements, DNA material, and detailed information on medication 
usage, family history, lifestyle and past medical history. Furthermore, we assessed the prevalence and incidence of 
retinopathy, nephropathy, neuropathy, and diabetic feet in cases. Using logistic regression models, we analyzed the 
association of 11 well known genetic risk variants with type 2 diabetes in our study.
Results: In total, 1886 patients with type 2 diabetes and 854 controls were included. Cases had worse anthropomet-
ric and metabolic profiles than controls. Patients in outpatient clinics had higher prevalence of macrovascular (41.9% 
vs. 34.8%; P = 0.002) and microvascular disease (63.8% vs. 20.7%) compared to patients from primary care. With the 
exception of the genetic variant in KCNJ11, all type 2 diabetes susceptibility variants had higher allele frequencies in 
subjects with type 2 diabetes than in controls.
Conclusions: In our study population, considerable rates of macrovascular and microvascular complications are 
present despite treatment. These prevalence rates are comparable to other type 2 diabetes populations. While plan-
ning genomics, we describe that 11 well-known type 2 diabetes genetic risk variants (in TCF7L2, PPARG-P12A, KCNJ11, 
FTO, IGF2BP2, DUSP9, CENTD2, THADA, HHEX, CDKAL1, KCNQ1) showed similar associations compared to literature. 
This study is well-suited for multiple omics analyses to further elucidate disease pathophysiology. Our overall goal is 
to increase the understanding of the underlying mechanisms of type 2 diabetes and its complications for developing 
new prediction, prevention, and treatment strategies.
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Background
Type 2 diabetes mellitus (T2DM) is a complex metabolic 
disease characterized by overweight, insulin resistance 
and beta-cell dysfunction [1–3]. Because of ageing and 
the rising prevalence of obesity, the incidence and prev-
alence of T2DM are increasing [4–7]. T2DM accounts 
for a large proportion of present and future health care 
expenditure in Western societies [5, 7, 8]. People affected 
by T2DM have an increased risk of cardiovascular events 
[9–13], and a poor prognosis after these events [14, 15]. 
In addition, T2DM gives rise to microvascular complica-
tions such as retinopathy, nephropathy and neuropathy 
[16–19]. We have collected a new large cohort of individ-
uals with and without T2DM with prospective follow-up 
in the Netherlands: the DiaGene study.
The care for T2DM in the Netherlands is organized 
in primary care by general practitioners and at hospital-
based outpatients clinics by medical specialists. This sys-
tematic care is based on local and international treatment 
guidelines aiming to reduce morbidity and mortality 
through optimal treatment of hyperglycemia and asso-
ciated metabolic complications, such as dyslipidemia, 
vascular dysfunction and high blood pressure [20, 21]. 
Treatment of these components has proven to reduce the 
risk of cardiovascular morbidity and mortality in T2DM 
[22–30]. However, a substantial residual risk remains. 
Improving knowledge on genetic, biochemical and envi-
ronmental (lifestyle and anthropometric) determinants of 
T2DM and its micro- and macrovascular complications 
can have large implications for prevention, treatment and 
prognosis of T2DM [2, 23, 31]. Through high throughput 
sequencing, about 80 common genetic variants associ-
ated with T2DM have been discovered [31, 32]. These 
common variants only explain 5–10% of the overall 
predisposition of T2DM [33]. There clearly is a need to 
expand these analyses to additional populations.
In this paper, we present the DiaGene study, a new, 
multicenter T2DM cohort study collected in the Neth-
erlands in both primary and secondary care. The main 
purpose of the DiaGene study is to study the analyses of 
genetic, biochemical and environmental determinants of 
T2DM and its complications. Here we describe the char-
acteristics of our population, the prevalence of complica-
tions and future perspectives.
Methods
Study design
The DiaGene study is a multicenter cohort study that 
was coordinated by the vascular section of internal medi-
cine of the Erasmus Medical Center and the Diabetes 
subunit of the Máxima Medical Center, and collected in 
the city of Eindhoven, The Netherlands. Eindhoven is a 
medium-sized city with 170,668 adult (>21 years) inhab-
itants in 2011. Both hospitals in Eindhoven participated 
in the DiaGene study: Catharina Hospital and Máxima 
Medical Center. In addition, the local Primary Care 
Diagnostic Centre participated. Hence, virtually all dia-
betes patients in Eindhoven were approached for inclu-
sion through this population-based approach. Between 
2006 and 2011, physicians at all three centers included a 
total of 2065 patients with T2DM. Of these, 179 patients 
were excluded from analysis. Reasons for exclusion 
where: no diabetes (n  =  1), Type 1 diabetes (n  =  30), 
Maturity-Onset Diabetes of the Young (n  =  4), Latent 
auto-immune diabetes in adults (n = 3), double inclusion 
(n = 77), post-pancreatitis diabetes (n = 3), refusal dur-
ing study period (n  =  2) and missing written informed 
consent (n = 59); resulting in a total of 1886 patients in 
the study population  (Additional file 1).
The control group consisted of two groups: (1) sub-
jects recruited via advertisement in local newspapers, 
and (2) subjects that where included through invitation 
of friends and self-reported unrelated family members of 
participating patients. Inclusion criteria for controls was 
age 55  years or older. Exclusion criteria were the pres-
ence of any kind of diabetes, use of metformin or Cush-
ing’s disease. Subjects who were approached had at least 
7 days of decision-time to fully reflect on research goals 
and methods using physician-provided information, 
before giving their written informed consent. Eventually, 
904 diabetes-free subjects participated as controls. Of 
these, 50 were excluded from all analyses based on miss-
ing written informed consent (n = 14), double inclusion 
(n = 17), and suspected or confirmed diagnosis of diabe-
tes (n = 19), resulting in a total of 854 controls included 
in the final population. This study was approved by the 
Medical Ethics Committees of the Erasmus MC, Catha-
rina Hospital and Máxima Medical Center. Written 
informed consent was obtained from all participants.
Keywords: Type 2 diabetes mellitus, Cardiovascular disease, Prospective follow-up, Complications, Genetics, Case–
control
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Definition of T2DM
Information on the diagnosis of T2DM was retrieved 
from the patient’s medical records. In accordance with 
American Diabetes Association—and World Health 
Organization—guidelines [34, 35], diabetes was defined 
as a fasting plasma glucose ≥7.0 mmol/L and/or a non-
fasting plasma glucose level ≥11.1 mmol/L measured at 
least at 2 separate time points, treatment with oral glu-
cose-lowering medication or insulin, and/or the diagno-
sis of T2DM as registered by a medical specialist. Persons 
with the diagnosis of type 1 diabetes (as derived from 
medical records and patient-questionnaires) or other 
types of diabetes mellitus were excluded from the study. 
Control subjects with fasting glucose  ≥7.0  mmol/L or 
glycated hemoglobin (HbA1c)  ≥47.5  mmol/mol were 
excluded. Information on T2DM status was checked by 
two investigators. If they did not reach consensus, the 
participant’s treating physician was consulted.
Medical and family history
Each participant filled out an extensive questionnaire on 
their medical history (history of diabetes, metabolic dis-
ease, vascular disease, medication use and intoxications) 
and ethnicity of their parents (Additional file 2). We clas-
sified a participant to be Caucasian if both parents were 
reported to be Caucasian. Furthermore, the participant’s 
family history regarding diabetes and cardiovascular dis-
ease and medication usage was recorded through the 
questionnaire.
Sample collection
A 20  cc Ethylene diamine tetra acetic (EDTA) fasting 
blood sample was taken from all participants. Samples 
were centrifuged (3000  rpm; 1800g for 15  min at 4  °C). 
Directly after centrifugation, the plasma and the buffy 
coat were separated and stored (at −80  °C) for DNA 
analysis and future measurements.
Diabetes and complications of diabetes
Data on body mass index (BMI) (kg/m2) and blood pres-
sure (mmHg) were extracted from medical records at 
inclusion. Similarly, laboratory results were extracted 
around time of inclusion and contained fasting glu-
cose, glycated hemoglobin (HbA1c), total cholesterol, 
low-density lipoprotein cholesterol (LDL-cholesterol), 
high-density lipoprotein-cholesterol (HDL-cholesterol), 
triglycerides, creatinine and urinary albumin/creatinine-
ratio. The majority of measurements were collected 
within 6 months prior to or after the actual date of inclu-
sion. To estimate kidney function, the estimated glomer-
ular filtration rate was calculated with the Modification 
of Diet in Renal Disease-formula. Information on the 
presence of cardiovascular disease in the patients treated 
in the hospital-based outpatient clinics was retrieved 
from their medical records. Cardiovascular disease com-
prised myocardial infarction, percutaneous coronary 
intervention/coronary arterial bypass graft (PCI/CABG), 
cerebrovascular accident, transient ischemic attack and 
peripheral arterial disease. PCI/CABG was defined as 
any invasive intervention to treat coronary arterial dis-
ease (PCI, CABG). Peripheral arterial disease was defined 
as an ankle-brachial index below 0.80 or below 0.90 with 
typical complaints, any intervention to treat peripheral 
arterial disease (supervised exercise training, stenting, 
bypass and percutaneous transluminal angioplasty, or 
the self-reported presence of intermittent claudication. 
Information on cardiovascular disease in patients from 
primary care and diabetes-free controls was based on 
self-reporting.
Microvascular complications were subdivided into 
retinopathy, nephropathy and neuropathy. Diabetic 
foot was additionally assessed. Retinopathy was scored 
according to the report of an ophthalmologist as absent 
or present and classified as non-proliferative, prolifera-
tive, or retinopathy treated with photo coagulation or 
intra-vitreal injections. Neuropathy was defined by a 
podotherapist, neurologist or the patients’ treating phy-
sician. Nephropathy was defined present when micro-
albuminuria [Albumin/creatinine-ratio (ACR)  ≥2.5 for 
men or ≥3.5 for women] was present at two of three con-
secutive measurements, or when high micro-albuminuria 
or macro-albuminuria was present at one measurement 
(ACR ≥12.5 for men or ≥17.5 for women). Diabetic foot 
was established by a podotherapist or physician accord-
ing to the SIMM’s classification [36]. All information 
on laboratory data, macrovascular, and microvascular 
events in case and control subjects at baseline that was 
retrieved from medical records was separately checked 
by two investigators. When they did not reach consensus, 
the participant’s physician was consulted.
Genotyping
DNA was isolated using the  Invisorb® Blood Universal 
Kit from Stratec Molecular (Berlin, Germany). Eleven 
well-known T2DM genetic risk variants were geno-
typed: TCF7L2(rs7903146), PPARG-P12A(rs1801282), 
DUSP9(rs594532), CENTD2(rs1552224), THADA 
(rs7578597), HHEX(rs1111875), CDKAL1(rs7754840) 
and KCNQ1(rs231362)which had previously been 
genotyped for replication in DIAGRAM [37], 
and KCNJ11(rs5219), IGF2BP2(rs4402960) and 
FTO(rs8050136). These risk variants were cho-
sen because of their relatively large effect sizes on 
T2DM risk in previous studies [32, 37–42]. Genotyp-
ing was performed with TaqMan allelic discrimination 
assays, designed and optimized by Applied Biosystems 
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(Foster City, CA, USA). Reactions were performed on the 
Taqman Prism 7900 HT platform.
Follow‑up data
Currently, we are finalizing the first collection of pro-
spective follow-up in our study population. This encom-
passes all anthropometric and laboratory measurements 
and data on metabolic, microvascular and macrovascular 
complications of T2DM and enables us to perform pro-
spective analyses.
Statistical analysis
Continuous variables are expressed as median with inter-
quartile range unless otherwise specified. Comparisons 
between groups were performed with Mann–Whitney 
U tests for continuous and χ2 tests for categorical data. 
Deviation from the Hardy–Weinberg equilibrium was 
assessed by χ2 testing. Associations of the genotypes 
with T2DM were tested using logistic regression models. 
We have calculated interaction effects of odds ratios for 
T2D to compare our results with previous genetic studies 
according to the method of Altman et al. [43]. All models 
were adjusted for age and sex. Additionally, models were 
adjusted for center of inclusion as a categorical covari-
ate. Cases and controls of non-Caucasian ethnicity were 
excluded from the genetic analyses. P values smaller than 
0.05 were considered to be statistically significant. Statis-
tical analysis was performed with SPSS-software version 
22.0 (SPSS, Chicago, IL, USA).
Results
General characteristics
The most relevant general characteristics of the cohort 
are displayed in Table  1. A total of 1886 patients with 
T2DM and 854 diabetes-free controls were included. Of 
all anthropometric measurements, 90.6 and 96.1% were 
performed within 6 and 12 months of inclusion, respec-
tively. Of laboratory data, 81.8 and 93.2% were meas-
ured within 6 and 12 months of inclusion, respectively. 
The cases and controls were of similar age. When com-
pared to controls, cases had higher BMI [29.5 (Inter-
quartile range (IQR) 26.4–32.7) vs. 25.5 (IQR 23.3–27.7) 
kg/m2; P < 0.001], higher HbA1c [50.8 (IQR 43.7–57.9) 
vs. 37.7 (IQR 36.1–39.3) mmol/mol; P  <  0.001], higher 
creatinine [78 (IQR 66–91) vs. 72 (IQR 63–81) µmol/L; 
P < 0.001], higher triglycerides [1.4 (IQR 0.9–1.9) vs. 1.2 
(IQR 0.9–1.5) mmol/L; P  <  0.001], lower HDL-choles-
terol [1.1 (IQR 0.9–1.3) vs. 1.4 (IQR 1.2–1.6) mmol/L; 
P  <  0.001] and lower LDL-cholesterol [2.4 (0.8) vs. 
3.6 (0.9) mmol/L; P  <  0.001]. A larger proportion of 
cases had reduced estimated glomerular filtration rate 
(19.7% vs. 4.7%, P  <  0.001) and prevalent macrovas-
cular disease (38.0% vs 8.3%, P  <  0.001) compared to 
diabetes-free controls. More cases had a first-degree 
relative with T2DM compared to controls (64.4% vs 
33.3%, P < 0.001). More baseline characteristics can be 
found in Table 1.
Primary care versus hospital‑based outpatient clinic
Table  2 shows baseline characteristics of patients with 
T2DM in primary care and hospital-based outpatient 
clinic. Patients with T2DM from the outpatient clinic 
had longer median duration of diabetes compared to 
primary care [12.5 (IQR 7.2–17.8) vs. 4.6 (IQR 1.2–7.9) 
years; P < 0.001] while they were diagnosed at a younger 
age [50.8 (10.8) vs. 58.4 (11.3) years, P  <  0.001]. At the 
outpatient clinic, participants had higher BMI [30.2 (IQR 
26.8–33.7) vs. 29.0 (IQR 26.0–32.0) kg/m2; P  <  0.001], 
HDL-cholesterol [1.2 (IQR 1.0–1.4) vs. 1.1 (IQR 0.9–1.3); 
P < 0.002], HbA1c [56.3 (IQR 48.1–64.5) vs. 48.6 (43.7–
53.6) mmol/mol; P  <  0.001] and higher creatinine [81 
(67–95) vs. 76 (64–88) µmol/L; P < 0.001]. Total choles-
terol [4.3 (0.9) vs 4.2 (0.9); P = 0.04] and LDL-cholesterol 
[2.6 (0.8) vs. 2.3 (0.8); P < 0.001] was higher in primary 
care patients. A larger proportion of patients with T2DM 
at the outpatient clinic had reduced estimated glomerular 
filtration rate (25.5% vs. 15.2%, P < 0.001), macrovascu-
lar disease (41.9% vs. 34.8%; P = 0.002) and microvascu-
lar disease (63.8% vs. 20.7%) compared to patients with 
T2DM from primary care. We could not retrieve reliable 
data on neuropathy nor diabetic foot in primary care 
population. More patients from the outpatient clinic had 
a first-degree relative with T2DM compared to controls 
(64.4% vs. 33.3%, P < 0.001).
Genetics
Table  3 shows the associations of 11 well-established 
genetic T2DM variants in our study population. Hardy–
Weinberg’s equilibrium was met for all variants. With 
the exception of the variant in KCNJ11, all T2DM sus-
ceptibility variants had higher allele frequencies in cases 
with T2DM than in controls. TCF7L2 showed the high-
est odds ratio for prevalent T2DM [OR 1.37 (95% CI 1.17, 
1.60; P  <  0.001]. These results were unaffected by addi-
tional correction for center of inclusion. After calculation 
of interaction effects, the associations of all genetic vari-
ants except for KCNJ11 did not significantly differ from 
the large scale meta-analyses of Morris et al. [44].
Discussion
In this manuscript, we present the baseline character-
istics and future perspectives of the DiaGene study, a 
new multi-centre cohort study with prospective follow-
up on biochemical and genetic determinants of T2DM 
and its complications. We show that the population is 
representing both primary and secondary care and that 
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despite treatment, considerable rates of macrovascular 
and microvascular complications are present. To further 
elucidate determinants of T2DM and its complications, 
multi-layer omics and prospective analyses will be of 
great value. Our study offers excellent opportunities to 
perform these analyses.
In the Netherlands, primary care practices are led by 
general practitioners, who are easily accessible and offer 
essential family medicine. Outpatient clinics of hospitals 
provide specialized care and require referral by the gen-
eral practitioner for reimbursement by insurance com-
panies. Therefore, complex and more severely affected 
patients will be referred to the hospital-based outpa-
tient clinics. This is reflected in the higher prevalence of 
micro- and macrovascular complications at the outpa-
tient clinics in our population.
The risk of microvascular disease can be reduced substan-
tially by glycemic control and general measures to prevent 
Table 1 General baseline characteristics of participants with and without T2DM
Table 1 shows baseline characteristics of participants from the DiaGene study
BMI body mass index, CVD cardiovascular disease, eGFR estimated glomerular filtration rate calculated with the Modification of Diet in Renal Disease-formula, IQR 
interquartile range, n-total total number of participants for whom information was available, T2DM type 2 diabetes mellitus
Cases Controls P value
Number of participants 1886 854
Female sex, n (%) 874 (46.4) 511 (59.8) <0.001
Age, year, median (IQR) 65.7 (58.5–72.9) 64.9 (60.4–69.4) 0.72
Age of onset diabetes, year, median (IQR) 55 (47–63) N/A N/A
Duration of diabetes, year, median (IQR) 8.1 (2.8–13.5) N/A N/A
BMI, kg/m2, median (IQR) 29.5 (26.4–32.7) 25.5 (23.3–27.7) <0.001
HbA1c, mmol/mol, median (IQR) 50.8 (43.7–57.9) 37.7 (36.1–39.3) <0.001
Diabetes treatment, % (n/n-available/n-missing)
 No glucose-lowering medication 19.2 (340/1772/114) N/A N/A
 Oral glucose-lowering agent 64.3 (1140/1773/113) N/A N/A
 Insulin 32.3 (572/1772/114) N/A N/A
Systolic blood pressure, mmHg, median (IQR) 140 (129–151) 137 (124–150) <0.001
Diastolic blood pressure, mmHg, median (IQR) 78 (71–85) 82 (76–89) <0.001
Total cholesterol, mmol/L, median (IQR) 4.2 (3.6–4.8) 5.6 (4.9–6.2) <0.001
Triglycerides, mmol/L, median (IQR) 1.4 (0.9–2.0) 1.2 (0.9–1.5) <0.001
HDL-cholesterol, mmol/L, median (IQR) 1.1 (0.9–1.3) 1.4 (1.2–1.6) <0.001
LDL-cholesterol, mmol/L, median (IQR) 2.3 (1.8–2.8) 3.5 (2.9–4.1) <0.001
Creatinine, µmol/L, median (IQR) 78 (66–91) 72 (63–81) <0.001
eGFR < 60 mL/min, % (n/n-available/n-missing) 21.2 (372/1756/130) 5.0 (40/795/59) <0.001
Cardiovascular disease, % (n/n-available/n-missing)
 Any macrovascular disease 38.0 (660/1738/148) 8.3 (68/824/30) <0.001
 Ischemic heart disease 28.0 (497/1778/108) 4.9 (41/842/12) <0.001
 Ischemic brain disease 12.0 (211/1757/129) 1.4 (12/840/14) <0.001
 Peripheral arterial disease 10.8 (193/1783/103) 2.2 (18/823/31) <0.001 
Microvascular diabetes complications, % (n/n-available/n-missing)
 Any microvascular disease 34.3 (561/1637/249) N/A N/A
 Diabetic retinopathy 17.3 (308/1778/108) N/A N/A
 Diabetic nephropathy 23.0 (387/1684/202) N/A N/A
Family history, % (n/n-available/n-missing)
 First-degree relative with T2DM 64.4 (1104/1714/172) 33.3 (269/809/45) <0.001
 First-degree relative with CVD 68.3 (1086/1590/296) 68.7 (519/755/99) 0.87
 Any relative with early-onset CVD 45.0 (780/1732/154) 41.5 (342/825 29) 0.09
Descent
 Caucasian descent, % (n/n-available/n-missing) 91.9 (1613/1755) 96.1 (810/843/11) <0.001
 Age of death father, year, median (IQR) 73 (65–82) 75 (67–84) <0.001
 Age of death mother, year, median (IQR) 78 (70–86) 81 (73–89) <0.001
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cardiovascular disease such as lifestyle, blood pressure and 
lipid optimization [22, 23, 25]. Rates of microvascular dis-
ease in our study at baseline were 17.3, 23.0 and 31% for 
retinopathy, nephropathy and neuropathy, respectively. This 
incidence of retinopathy in T2DM is comparable to a report 
from the Dutch National Institute for Public Health and the 
Environment [45] and in line with a worldwide meta-anal-
yses for diabetes with a duration of less than 10 years [46], 
but higher than in a screening study for T2DM from the 
Netherlands [47]. In the latter study, the duration of T2DM 
was short and this probably explains the difference. For 
nephropathy, our rate is slightly lower than in the United 
Kingdom Prospective Diabetes Study (25%), also probably 
because of shorter follow-up [16]. Our primary care popula-
tion appeared to have lower rates of nephropathy compared 
to studies on prevalent diabetes and newly diagnosed dia-
betes in patients of general practitioners in the Netherlands 
[47, 48]. Although the single urinary measurement-based 
Table 2 General baseline characteristics of participants with and without T2DM
Table 2 shows baseline characteristics of participants from the DiaGene study in both primary care and hospital-based outpatient clinic
BMI body mass index, CVD cardiovascular disease, eGFR estimated glomerular filtration rate calculated with the Modification of Diet in Renal Disease-formula, IQR 
interquartile range, n-total total number of participants for whom information was available, T2DM type 2 diabetes mellitus
Primary care Outpatient clinic P value
Number of participants 1056 830
Female sex, n (%) 494 (46.8) 380 (45.9) 0.71
Age, year, median (IQR) 65.5 (58.1–72.9) 65.9 (58.9–72.9) 0.66
Age of onset diabetes, year, median (IQR) 59 (51–67) 51 (44–59) <0.001
Duration of diabetes, year, median (IQR) 4.5 (1.2–7.9) 12.5 (7.2–17.8) <0.001
BMI, kg/m2, median (IQR) 29.0 (26.0–32.0) 30.2 (26.8–33.7) <0.001
HbA1c, mmol/mol, median (IQR) 48.6 (43.7–53.6) 56.3 (48.1–64.5) <0.001
Diabetes treatment, % (n/n-available/n-missing)
 No medication 24.7 (248/1004/52) 12.0 (92/768/62) <0.001
 Oral glucose-lowering agents 72.9 (732/1004/52) 53.1 (408/768/62) <0.001
 Insulin 8.6 (86/1004/52) 63.3 (486/768/62) <0.001
Systolic blood pressure, mmHg, median (IQR) 146 (133–159) 134 (126–143) <0.001
Diastolic blood pressure, mmHg, median (IQR) 79 (72–86) 75 (70–80) <0.001
Total cholesterol, mmol/L, median (IQR) 4.2 (3.6–4.9) 4.1 (3.6–4.6) 0.047
Triglycerides, mmol/L, median (IQR) 1.4 (0.9–1.9) 1.5 (1.0–2.0) 0.104
HDL-cholesterol, mmol/L, median (IQR) 1.1 (0.9–1.3) 1.2 (1.0–1.4) 0.002
LDL-cholesterol, mmol/L, median (IQR) 2.5 (2.0–3.1) 2.1 (1.7–2.6) <0.001
Creatinine, µmol/L, median (IQR) 76 (64–88) 81 (67–95) <0.001
eGFR < 60 mL/min % (n/n available/n-missing) 16.4 (160/978/78) 27.2 (212/778/52) <0.001
Cardiovascular disease, % (n/n-available/n-missing)
 Any macrovascular disease 34.8 (335/963/93) 41.9 (325/775/55) 0.002
 Ischemic heart disease 25.2 (252/1000/56) 31.5 (245/778/52) 0.004
 Ischemic brain disease 12.7 (124/973/83) 11.1 (87/784/46) 0.302
 Peripheral arterial disease 9.2 (88/958/98) 12.7 (105/825/5) 0.0181
Microvascular diabetes complications, % (n/n-available/n-missing)
 Any microvascular disease 20.7 (172/830/226) 48.2 (389/807/23) <0.001
 Diabetic retinopathy 6.1 (59/962/94) 30.5 (249/816/15) <0.001
 Diabetic nephropathy 15.4 (134/868/188) 31.0 (253/816/15) <0.001
 Neuropathy Unknown 31.2 (238/762/68) N/A
Family history, % (n/n-available/n-missing)
 First-degree relative with T2DM 61.4 (586/955/101) 68.2 (518/759/71) 0.003
 First-degree relative with CVD 67.6 (608/899/157) 69.2 (478/691/139) 0.712
 Any relative with early-onset CVD 45.0 (436/968/88) 45.0 (344/764/66) 1.0
Descent
 Caucasian descent, % (n/n-available/n-missing) 90.3 (892/988/132 ) 94.0 (721/767/63) 0.005
 Age of death father, year, median (IQR) 73 (65–82) 73 (65–82) 0.728
 Age of death mother, year, median (IQR) 79 (72–87) 77 (69–85) 0.055
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prevalence rates in the latter could be an explanation for this 
discrepancy. The percentage of patients with T2DM and 
neuropathy in our population (31%) is lower compared to 
a prospective study (50%) with 25 years of follow-up from 
diagnosis [19] and comparable to a cross-sectional study on 
peripheral neuropathy in the United Kingdom [49].
The risk of macrovascular disease in T2DM can be suc-
cessfully reduced by applying lifestyle interventions, lipid 
lowering therapies and antihypertensive treatment. The 
relationship with glycemic control is more complex. Even 
though glycemic control epidemiologically is strongly 
related to cardiovascular disease in T2DM, interventions 
applying strict glycemic control were unsuccessful [22, 
50] or even showed adverse effects [51]. Macrovascular 
disease rates in our population with T2DM is comparable 
to previous reports in the Netherlands [45, 52], but lower 
than in an interview-based study in diabetes patients in 
the USA [53]. Our population is on average 5 years older 
than the patients in this American study, and also con-
tains a significant proportion of patients from outpatient 
clinics having further progressed disease.
T2DM and its complications are multifactorial in 
their pathophysiology’s. Genetics, epigenetics, biologi-
cal mechanisms and environmental factors are probably 
interacting at multiple levels. Therefore a pathway-based 
approach in well-defined cohorts is needed, supported 
by full use of information technology. High through-
put research has been mainly focused on genome wide 
genetic associations. This has elucidated interesting asso-
ciations. Yet the results only explain disease susceptibil-
ity to a small extent [31, 33]. We are planning to perform 
genome-wide association analysis in the near future. The 
quality control of this future genomic work will include 
analyses of the genetic-based ethnic background to defin-
itively determine population sub-structures. Here, we 
restricted our analyses of well-known genetic T2DM risk 
variants to the sub-group of self-reported Caucasians. 
These DNA polymorphisms showed similar associa-
tions in our mainly Caucasian population as in previous 
extensive meta-analyses: most genetic variants had simi-
lar direction of their associations as earlier reported and 
for TCF7L2, THADA, KCNQ1 and CDKAL1 this was 
Table 3 Allele frequencies, odds ratios and 95% confidence intervals of genetic variants and risk of T2D in DiaGene, origi-
nal discovery studies and most recent meta-analysis of genome-wide-association studies
Table shows odds ratios of association with type 2 diabetes for different known risk alleles tested in our study population. Logistic regression analysis is age, sex and 
center of inclusion-adjusted
Significant odd ratios of association with type 2 diabetes are displayed in italic
CEU Caucasian, OR odds-ratio, CI confidence interval
* Statistically significant difference of odds ratio in association of genetic variant with T2DM when compared to Morris et al. [52]
Locus‑marker Risk allele/
other
DiaGene Original discovery study results Morris et al. [52]
Risk allele 
frequency case/
control/total
OR (95% CI) Ceu‑hap map OR (95% CI) Reference 
original study
OR (95% CI)
CDKAL1-rs7754840 C/G 0.36/0.31/0.35 1.23 (1.06–1.44); 
P = 0.006
0.31 1.12 (1.08–1.16) [38, 39, 41, 42] 1.15 (1.11–1.19)
CENTD2-rs1552224 A/C 0.86/0.86/0.86 0.95 (0.77–1.16); 
P = 0.60
0.88 1.14 (1.11–1.17) [37] 1.13 (1.08–1.19)
DUSP9-rs5945326 G/A 0.22/0.22/0.22 1.02 (0.88–1.18); 
P = 0.77
0.12 1.27 (1.18–1.37) [37] N/A (on X-chro-
mosome)
FTO-rs8050136 A/C 0.40/0.38/0.39 1.06 (0.91–1.22); 
P = 0.45
0.45 1.15 (1.09–1.22) [41] 1.11 (1.07–1.15)
HHEX-rs1111875 C/T 0.64/0.63/0.63 1.01 (0.87–1.16); 
P = 0.95
0.56 1.13 (1.08–1.17) [38] 1.15 (1.11–1.18)
IGFBP2-rs4402960 T/G 0.33/0.32/0.33 1.01 (0.87–1.18); 
P = 0.89
0.29 1.17 (1.10–1.25) [41] 1.13 (1.09–1.17)
KCNJ11-rs5219 T/C 0.37/0.39/0.37 0.92 (0.80–1.07); 
P = 0.29
0.50 1.15 (1.09–1.21) [38] 1.08 (1.05–1.12)
KCNQ1-rs231362 G/A 0.53/0.49/0.52 1.16 (1.00–1.34); P 
= 0.04*
0.52 1.08 (1.06–1.10) [40] 1.11 (1.07–1.16)*
PPARG-P12A-rs1801282 C/G 0.89/0.88/0.89 1.13 (0.91–1.42); 
P = 0.27
0.92 1.14 (1.08–1.20) [38, 39, 42] 1.16 (1.11–1.22)
TCF7L2 rs7903146 T/C 0.36/0.28/0.34 1.37 (1.17–1.60); 
P < 0.001
0.25 1.37 (1.28–1.47) [41] 1.40 (1.35–1.46)
THADA rs7578597 T/C 0.91/0.88/0.90 1.36 (1.08–1.71); 
P = 0.01
0.92 1.15 (1.10–1.20) [41] 1.14 (1.08–1.22)
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significant [32, 44, 54]. KCNJ11 and CENTD2 showed a 
slight but not statistically significant opposite association 
to what has previously described, with estimates close to 
1 and confidence intervals embracing the estimates from 
literature [32]. Except for KCNJ11, all genetic variants 
had non-significant interaction effects for odds ratios of 
T2DM-risk variants compared to the latest meta-analy-
sis [44]. The significant difference for KCNJ11 can be an 
effect of population-specific variance, differences in envi-
ronmental factors, age or interactions of these factors 
with the genetic variant [44].
To study the aetiology of T2DM and its complica-
tions we need well phenotyped cohorts with prospec-
tive follow-up. Our population has these characteristics. 
We therefore plan to analyse several omics layers for 
their associations with T2DM and its complications. We 
are currently measuring total N-glycomics with matrix-
assisted laser desorption–ionization-time of flight 
(MALDI-TOF), matrix-assisted laser desorption–ioni-
zation-Fourier transform ion cyclotron resonance mass 
spectrometry (MALDI-FTICR) [55] and IgG-glycomics 
with ultra-performance liquid chromatography [56]. 
In the near future, we aim to include lipidomics, with a 
focus on lipoprotein(a), metabolomics, and proteomics. 
Also we plan to perform genomics using the Illumina 
chip, for mendelian randomization and multilayer inter-
action analyses. The overall goal being to elucidate new 
pathophysiological pathways for prediction, prevention 
and treatment of T2DM.
Although we have performed our study with preci-
sion, we need to consider a number of limitations. A large 
majority of our population is of self-reported Caucasian 
ethnicity, which limits extending conclusions from our 
analyses to non-Caucasian populations. However, it also 
makes our analyses less vulnerable to genetic population 
stratification bias. Self-reported Caucasian mono-ethnicity 
in two generations results in a very limited risk of misclas-
sifying genetic admixtures [57, 58]. In addition, a small 
proportion of diabetes-free subjects where recruited by 
asking T2DM subjects to invite unrelated family mem-
bers and friends. Hence, absence of family ties was self-
reported, with a small possibility of hidden relatedness. 
In the near future, we will perform genome-wide associa-
tion analysis, which will allow us to perform formal quality 
control and accurately account for hidden relatedness and 
genetic population stratification bias [59]. Another limita-
tion of this study was our inability to retrieve information 
on neuropathy in primary care setting. Conclusions on 
neuropathy are therefore restricted to the secondary care 
setting. We have made extensive efforts to optimise the 
reliability of our data by having two independent investi-
gators collect the data and reach consensus. This means 
we did have to rely on common clinical practice and 
adequate record keeping in primary and secondary care. 
For macrovascular events in primary care we had to rely 
on self-reported data. For validation, we have therefore 
checked self-reported myocardial infarction data from 
hospital-based participants and found that in only 6.0% of 
participants with self-reported myocardial infarction this 
diagnosis was not confirmed in hospital data. These events 
have therefore been scored as missing. Underestimation 
of the incidence of myocardial infarction based on hospi-
tal discharge data has however been described before [60]. 
And although the questionnaire on lifestyle, medication, 
clinical events and family history was straight-forward and 
easy to use, it is not an externally validated questionnaire. 
At last, our preliminary genetic results had approximately 
10% missing values. We are currently collecting additional 
samples from the participants whose DNA was not avail-
able at the time of the current genetic analysis to improve 
our genetic analysis. Further strengths of our study are the 
meticulous hands-on medical file review for each patient 
by two separate physicians, which produced high-quality 
data that enable us to research both T2DM itself as well as 
its complications in great detail. Currently, we are finaliz-
ing the first collection prospective follow up on all T2DM 
complications. The prospective cohort setting with con-
current inclusion of diabetes-free individuals at baseline, 
will allow us to perform cross-sectional and prospective 
end-point analyses to study aetiology and progression of 
type 2 diabetes and its complications.
Conclusion
In conclusion, this manuscript describes the design and 
baseline characteristics of the DiaGene study, a large 
multi-centre prospective follow-up cohort study on envi-
ronmental, biochemical and genetic risk factors of T2DM 
and related vascular complications. By studying both 
clinical and complex biochemical parameters with a cur-
rent focus on glycomics, genomics and lipidomics, the 
DiaGene study aims to contribute to the pathophysiolog-
ical understanding of T2DM and all its vascular compli-
cations in a prospective case–control setting.
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